$70.80M Market Cap.
GBIO Market Cap. (MRY)
GBIO Shares Outstanding (MRY)
GBIO Assets (MRY)
Total Assets
$231.20M
Total Liabilities
$144.99M
Total Investments
$108.92M
GBIO Income (MRY)
Revenue
$19.89M
Net Income
-$131.67M
Operating Expense
$162.28M
GBIO Cash Flow (MRY)
CF Operations
-$88.56M
CF Investing
$94.53M
CF Financing
$250.00K
GBIO Dividends (MRY)
Period | Dividends | Yield % | Growth % | Payout Ratio | Coverage Ratio |
|---|---|---|---|---|---|
2024 | $0 | 0% | 0% | 0% | - |
2023 | $0 | 0% | 0% | 0% | - |
2022 | $0 | 0% | 0% | 0% | - |
2021 | $0 | 0% | 0% | 0% | - |
2020 | $0 | 0% | - | 0% | - |
GBIO Balance Sheet (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Total Assets | $231,197,000 (-38.31%) | $374,758,000 (-0.40%) | $376,264,000 (-21.08%) | $476,771,000 (62.08%) |
Assets Current | $192,903,000 (-29.24%) | $272,618,000 (-5.02%) | $287,016,000 (-24.31%) | $379,186,000 (41.63%) |
Assets Non-Current | $38,294,000 (-62.51%) | $102,140,000 (14.45%) | $89,248,000 (-8.54%) | $97,585,000 (269.36%) |
Goodwill & Intangible Assets | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Shareholders Equity | $86,204,000 (-57.56%) | $203,128,000 (-28.09%) | $282,493,000 (-26.00%) | $381,746,000 (42.44%) |
Property Plant & Equipment Net | $35,603,000 (-62.78%) | $95,651,000 (17.47%) | $81,423,000 (-10.55%) | $91,029,000 (282.78%) |
Cash & Equivalents | $78,453,000 (8.61%) | $72,237,000 (-26.93%) | $98,863,000 (-74.04%) | $380,837,000 (486.44%) |
Accumulated Other Comprehensive Income | $159,000 (-41.97%) | $274,000 (430.12%) | -$83,000 (0%) | $0 (0%) |
Deferred Revenue | $39,743,000 (-27.56%) | $54,861,000 (0%) | $0 (0%) | $0 (0%) |
Total Investments | $108,922,000 (-44.97%) | $197,918,000 (6.45%) | $185,920,000 (0%) | $0 (0%) |
Investments Current | $108,922,000 (-44.97%) | $197,918,000 (6.45%) | $185,920,000 (0%) | $0 (0%) |
Investments Non-Current | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Inventory | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Trade & Non-Trade Receivables | $1,224,000 (-69.09%) | $3,960,000 (902.53%) | $395,000 (0%) | $0 (0%) |
Trade & Non-Trade Payables | $1,408,000 (-39.98%) | $2,346,000 (254.38%) | $662,000 (-67.28%) | $2,023,000 (657.68%) |
Accumulated Retained Earnings (Deficit) | -$703,045,000 (-23.04%) | -$571,377,000 (-28.47%) | -$444,765,000 (-44.35%) | -$308,126,000 (-63.05%) |
Tax Assets | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Tax Liabilities | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Total Debt | $93,560,000 (-4.43%) | $97,894,000 (19.81%) | $81,707,000 (1.09%) | $80,825,000 (0%) |
Debt Current | $13,006,000 (60.17%) | $8,120,000 (14.59%) | $7,086,000 (53.78%) | $4,608,000 (0%) |
Debt Non-Current | $80,554,000 (-10.27%) | $89,774,000 (20.31%) | $74,621,000 (-2.09%) | $76,217,000 (0%) |
Total Liabilities | $144,993,000 (-15.52%) | $171,630,000 (83.03%) | $93,771,000 (-1.32%) | $95,025,000 (263.50%) |
Liabilities Current | $35,055,000 (-12.17%) | $39,914,000 (108.43%) | $19,150,000 (1.82%) | $18,808,000 (67.63%) |
Liabilities Non-Current | $109,938,000 (-16.53%) | $131,716,000 (76.51%) | $74,621,000 (-2.09%) | $76,217,000 (410.77%) |
GBIO Income Statement (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Revenues | $19,892,000 (236.92%) | $5,904,000 (0%) | $0 (0%) | $0 (0%) |
Cost of Revenue | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Selling General & Administrative Expense | $37,780,000 (-25.70%) | $50,850,000 (14.36%) | $44,464,000 (31.34%) | $33,854,000 (49.92%) |
Research & Development Expense | $61,305,000 (-34.52%) | $93,617,000 (-3.21%) | $96,718,000 (13.46%) | $85,247,000 (45.64%) |
Operating Expenses | $162,282,000 (12.33%) | $144,467,000 (2.33%) | $141,182,000 (18.54%) | $119,101,000 (46.83%) |
Interest Expense | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Income Tax Expense | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Loss Income from Discontinued Operations | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Consolidated Income | -$131,668,000 (-3.99%) | -$126,612,000 (7.34%) | -$136,639,000 (-14.68%) | -$119,151,000 (-47.97%) |
Net Income to Non-Controlling Interests | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Income | -$131,668,000 (-3.99%) | -$126,612,000 (7.34%) | -$136,639,000 (-14.68%) | -$119,151,000 (-47.97%) |
Preferred Dividends Income Statement Impact | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Income Common Stock | -$131,668,000 (-3.99%) | -$126,612,000 (7.34%) | -$136,639,000 (-14.68%) | -$119,151,000 (-47.97%) |
Weighted Average Shares | $66,624,249 (3.32%) | $64,483,520 (10.96%) | $58,114,893 (3.23%) | $56,295,409 (106.54%) |
Weighted Average Shares Diluted | $66,624,249 (3.32%) | $64,483,520 (10.96%) | $58,114,893 (3.23%) | $56,295,409 (106.54%) |
Earning Before Interest & Taxes (EBIT) | -$131,668,000 (-3.99%) | -$126,612,000 (7.34%) | -$136,639,000 (-14.68%) | -$119,151,000 (-47.97%) |
Gross Profit | $19,892,000 (236.92%) | $5,904,000 (0%) | $0 (0%) | $0 (0%) |
Operating Income | -$142,390,000 (-2.76%) | -$138,563,000 (1.86%) | -$141,182,000 (-18.54%) | -$119,101,000 (-46.83%) |
GBIO Cash Flow Statement (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Net Cash Flow from Investing | $94,529,000 (1074.73%) | -$9,698,000 (94.96%) | -$192,515,000 (-199.72%) | $193,047,000 (194.08%) |
Net Cash Flow from Financing | $250,000 (-99.30%) | $35,817,000 (175.75%) | $12,989,000 (-93.95%) | $214,671,000 (-33.56%) |
Net Cash Flow from Operations | -$88,563,000 (-67.91%) | -$52,745,000 (48.52%) | -$102,448,000 (-11.57%) | -$91,821,000 (-30.91%) |
Net Cash Flow / Change in Cash & Cash Equivalents | $6,216,000 (123.35%) | -$26,626,000 (90.56%) | -$281,974,000 (-189.26%) | $315,897,000 (561.47%) |
Net Cash Flow - Business Acquisitions and Disposals | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Cash Flow - Investment Acquisitions and Disposals | $96,734,000 (4304.00%) | -$2,301,000 (98.75%) | -$183,714,000 (-192.37%) | $198,900,000 (199.61%) |
Capital Expenditure | -$2,205,000 (70.19%) | -$7,397,000 (15.95%) | -$8,801,000 (-50.37%) | -$5,853,000 (-6.07%) |
Issuance (Repayment) of Debt Securities | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Issuance (Purchase) of Equity Shares | $436,000 (-98.81%) | $36,546,000 (168.33%) | $13,620,000 (-93.68%) | $215,626,000 (-0.85%) |
Payment of Dividends & Other Cash Distributions | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Effect of Exchange Rate Changes on Cash | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Share Based Compensation | $14,609,000 (-39.98%) | $24,341,000 (-0.45%) | $24,452,000 (36.93%) | $17,857,000 (112.28%) |
Depreciation Amortization & Accretion | $4,931,000 (-6.31%) | $5,263,000 (2.59%) | $5,130,000 (13.20%) | $4,532,000 (32.05%) |
GBIO Financial Metrics (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Gross Margin | 100.00% (0.00%) | 100.00% | - | - |
Profit Margin | -661.90% (69.13%) | -2144.50% | - | - |
EBITDA Margin | -637.10% (69.00%) | -2055.40% | - | - |
Return on Average Equity (ROAE) | -120.20% (-129.83%) | -52.30% (-21.35%) | -43.10% (-51.76%) | -28.40% (34.41%) |
Return on Average Assets (ROAA) | -51.10% (-60.69%) | -31.80% (4.50%) | -33.30% (-35.92%) | -24.50% (18.60%) |
Return on Sales (ROS) | -661.90% (69.13%) | -2144.50% | - | - |
Return on Invested Capital (ROIC) | -47.30% (-29.59%) | -36.50% (22.67%) | -47.20% (43.13%) | -83.00% (-62.43%) |
Dividend Yield | 0% (0%) | 0% (0%) | 0% (0%) | 0% (0%) |
Price to Earnings Ratio (P/E) | -0.54 (36.46%) | -0.84 (49.64%) | -1.67 (49.94%) | -3.34 (65.24%) |
Price to Sales Ratio (P/S) | 3.55 (-80.30%) | 18.02 | - | - |
Price to Book Ratio (P/B) | 0.82 (52.89%) | 0.54 (-35.07%) | 0.83 (-21.61%) | 1.05 (-78.56%) |
Debt to Equity Ratio (D/E) | 1.68 (99.05%) | 0.84 (154.52%) | 0.33 (33.33%) | 0.25 (154.08%) |
Earnings Per Share (EPS) | -1.98 (-1.02%) | -1.96 (16.60%) | -2.35 (-10.85%) | -2.12 (28.14%) |
Sales Per Share (SPS) | 0.3 (225.00%) | 0.09 (0%) | 0 (0%) | 0 (0%) |
Free Cash Flow Per Share (FCFPS) | -1.36 (-45.98%) | -0.93 (51.25%) | -1.91 (-10.32%) | -1.74 (37.50%) |
Book Value Per Share (BVPS) | 1.29 (-58.92%) | 3.15 (-35.20%) | 4.86 (-28.31%) | 6.78 (-31.04%) |
Tangible Assets Book Value Per Share (TABVPS) | 3.47 (-40.30%) | 5.81 (-10.23%) | 6.47 (-23.56%) | 8.47 (-21.53%) |
Enterprise Value Over EBIT (EV/EBIT) | -1 (0.00%) | -1 (0.00%) | -1 (0%) | 0 (0%) |
Enterprise Value Over EBITDA (EV/EBITDA) | -1.11 (-50.34%) | -0.74 (45.01%) | -1.34 (-177.11%) | -0.48 (97.03%) |
Asset Turnover | 0.08 (413.33%) | 0.01 (0%) | 0 (0%) | 0 (0%) |
Current Ratio | 5.5 (-19.43%) | 6.83 (-54.43%) | 14.99 (-25.66%) | 20.16 (-15.51%) |
Dividends | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Free Cash Flow (FCF) | -$90,768,000 (-50.92%) | -$60,142,000 (45.94%) | -$111,249,000 (-13.90%) | -$97,674,000 (-29.10%) |
Enterprise Value (EV) | $140,770,391 (56.95%) | $89,690,728 (-49.25%) | $176,714,199 (218.07%) | $55,558,129 (-95.59%) |
Earnings Before Tax (EBT) | -$131,668,000 (-3.99%) | -$126,612,000 (7.34%) | -$136,639,000 (-14.68%) | -$119,151,000 (-47.97%) |
Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) | -$126,737,000 (-4.44%) | -$121,349,000 (7.73%) | -$131,509,000 (-14.74%) | -$114,619,000 (-48.68%) |
Invested Capital | $211,249,000 (-41.40%) | $360,501,000 (6.04%) | $339,958,000 (115.23%) | $157,951,000 (-27.54%) |
Working Capital | $157,848,000 (-32.17%) | $232,704,000 (-13.13%) | $267,866,000 (-25.67%) | $360,378,000 (40.49%) |
Tangible Asset Value | $231,197,000 (-38.31%) | $374,758,000 (-0.40%) | $376,264,000 (-21.08%) | $476,771,000 (62.08%) |
Market Capitalization | $70,800,391 (-35.06%) | $109,028,728 (-53.31%) | $233,531,199 (-42.04%) | $402,921,129 (-69.45%) |
Average Equity | $109,511,000 (-54.77%) | $242,117,000 (-23.68%) | $317,257,750 (-24.51%) | $420,273,500 (125.94%) |
Average Assets | $257,781,000 (-35.25%) | $398,137,500 (-3.02%) | $410,520,750 (-15.60%) | $486,419,250 (82.02%) |
Invested Capital Average | $278,527,000 (-19.73%) | $346,977,250 (19.83%) | $289,566,750 (101.68%) | $143,574,750 (-8.87%) |
Shares | 66,792,822 (1.08%) | 66,078,017 (11.20%) | 59,422,697 (4.42%) | 56,909,764 (22.34%) |
